Jeffrey Y.C. Wong

7.6k total citations · 1 hit paper
214 papers, 5.4k citations indexed

About

Jeffrey Y.C. Wong is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jeffrey Y.C. Wong has authored 214 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 112 papers in Radiology, Nuclear Medicine and Imaging, 71 papers in Oncology and 64 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jeffrey Y.C. Wong's work include Advanced Radiotherapy Techniques (53 papers), Radiopharmaceutical Chemistry and Applications (52 papers) and Hematopoietic Stem Cell Transplantation (30 papers). Jeffrey Y.C. Wong is often cited by papers focused on Advanced Radiotherapy Techniques (53 papers), Radiopharmaceutical Chemistry and Applications (52 papers) and Hematopoietic Stem Cell Transplantation (30 papers). Jeffrey Y.C. Wong collaborates with scholars based in United States, Italy and Canada. Jeffrey Y.C. Wong's co-authors include Timothy E. Schultheiss, An Liu, Lawrence E. Williams, Andrew Raubitschek, John E. Shively, Anna M. Wu, Chunhui Han, Paul J. Yazaki, Yi‐Jen Chen and Richard D. Pezner and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Jeffrey Y.C. Wong

209 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study

2021 237 citations Michael J. Morris, Steven P. Rowe et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeffrey Y.C. Wong United States	43	2.7k	1.8k	1.5k	1.3k	934	214	5.4k
Yee Ung Canada	32	1.3k 0.5×	2.8k 1.6×	2.1k 1.4×	900 0.7×	880 0.9×	94	5.1k
Françoise Kraeber‐Bodéré France	40	2.7k 1.0×	1.0k 0.6×	1.4k 0.9×	260 0.2×	713 0.8×	215	4.9k
John Staffurth United Kingdom	31	1.2k 0.5×	2.8k 1.6×	1.1k 0.7×	728 0.6×	850 0.9×	117	4.4k
Michael Laßmann Germany	45	4.5k 1.7×	2.0k 1.1×	1.3k 0.8×	1.2k 0.9×	501 0.5×	201	7.0k
Yvette L. Kasamon United States	34	2.3k 0.9×	1.1k 0.6×	2.1k 1.4×	191 0.1×	620 0.7×	99	5.9k
Timothy E. Schultheiss United States	59	3.3k 1.3×	5.6k 3.2×	1.2k 0.8×	4.3k 3.3×	550 0.6×	176	9.4k
Joseph G. Rajendran United States	29	2.0k 0.7×	1.1k 0.6×	902 0.6×	293 0.2×	398 0.4×	74	3.8k
Malik E. Juweid United States	31	3.5k 1.3×	1.8k 1.0×	2.7k 1.8×	157 0.1×	737 0.8×	126	8.1k
Mark De Ridder Belgium	39	1.7k 0.6×	2.1k 1.2×	1.4k 0.9×	2.1k 1.6×	715 0.8×	199	5.2k
Neeta Pandit‐Taskar United States	44	2.8k 1.1×	1.7k 1.0×	2.2k 1.4×	261 0.2×	878 0.9×	215	6.0k

Countries citing papers authored by Jeffrey Y.C. Wong

Since Specialization

Citations

This map shows the geographic impact of Jeffrey Y.C. Wong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Y.C. Wong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Y.C. Wong more than expected).

Fields of papers citing papers by Jeffrey Y.C. Wong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Y.C. Wong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Y.C. Wong. The network helps show where Jeffrey Y.C. Wong may publish in the future.

Co-authorship network of co-authors of Jeffrey Y.C. Wong

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Y.C. Wong. A scholar is included among the top collaborators of Jeffrey Y.C. Wong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Y.C. Wong. Jeffrey Y.C. Wong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Akhavan, David, John D. Jeppson, Brenda Aguilar, et al.. (2024). Evaluation of the Immunomodulatory Effects of Radiation for Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme. Cells. 13(13). 1075–1075. 3 indexed citations

Hernandez, Matthew C., Paul J. Yazaki, Joanne Mortimer, et al.. (2023). Pilot study of HER2 targeted 64Cu-DOTA-tagged PET imaging in gastric cancer patients. Nuclear Medicine Communications. 44(12). 1151–1155. 4 indexed citations

Dorff, Tanya B., Saro Kasparian, Sandy Liu, et al.. (2023). Difficulties in Defining Oligometastatic Prostate Cancer: Implications for Clinical Trial Accrual and Community Practice Adoption of Metastasis-Directed Therapy Approaches. Journal of Clinical Medicine. 12(5). 2011–2011. 1 indexed citations

Parsons, David, Tze Yee Lim, Jose R. Teruel, et al.. (2023). Considerations for intensity modulated total body or total marrow and lymphoid irradiation. Clinical and Translational Radiation Oncology. 43. 100674–100674. 4 indexed citations

Morris, Michael J., Steven P. Rowe, Michael A. Gorin, et al.. (2021). Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study. Clinical Cancer Research. 27(13). 3674–3682. 237 indexed citations breakdown →

Kujawski, Maciej, Mark E. Sherman, Susanta Hui, et al.. (2020). Potent immunomodulatory effects of an anti-CEA-IL-2 immunocytokine on tumor therapy and effects of stereotactic radiation. OncoImmunology. 9(1). 1724052–1724052. 17 indexed citations

Leong, Lucille, Lawrence D. Wagman, Stephen Shibata, et al.. (2017). Phase I/II Trial of Anticarcinoembryonic Antigen Radioimmunotherapy, Gemcitabine, and Hepatic Arterial Infusion of Fluorodeoxyuridine Postresection of Liver Metastasis for Colorectal Carcinoma. Cancer Biotherapy and Radiopharmaceuticals. 32(7). 258–265. 11 indexed citations

Wong, Patty, Lin Li, Junie Chea, et al.. (2017). Synthesis, Positron Emission Tomography Imaging, and Therapy of Diabody Targeted Drug Lipid Nanoparticles in a Prostate Cancer Murine Model. Cancer Biotherapy and Radiopharmaceuticals. 32(7). 247–257. 13 indexed citations

Feng, Jianguo, Shirong Zhang, Kan Wu, et al.. (2016). Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non–Small Cell Lung Cancer. Molecular Cancer Therapeutics. 15(5). 842–853. 13 indexed citations

10.

Ravandi, Farhad, Megan Othus, Susan O’Brien, et al.. (2015). Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60. Blood. 126(23). 796–796. 11 indexed citations

11.

Chen, Xufeng, Patty Wong, Eric H. Radany, et al.. (2012). Suberoylanilide Hydroxamic Acid as a Radiosensitizer through Modulation of RAD51 Protein and Inhibition of Homology-Directed Repair in Multiple Myeloma. Molecular Cancer Research. 10(8). 1052–1064. 40 indexed citations

12.

Chen, Xufeng, Jeffrey Y.C. Wong, Patty Wong, & Eric H. Radany. (2011). Low-Dose Valproic Acid Enhances Radiosensitivity of Prostate Cancer through Acetylated p53-Dependent Modulation of Mitochondrial Membrane Potential and Apoptosis. Molecular Cancer Research. 9(4). 448–461. 62 indexed citations

13.

Chen, Xufeng, Patty Wong, Eric H. Radany, & Jeffrey Y.C. Wong. (2009). HDAC Inhibitor, Valproic Acid, Induces p53-Dependent Radiosensitization of Colon Cancer Cells. Cancer Biotherapy and Radiopharmaceuticals. 24(6). 689–699. 81 indexed citations

14.

Williams, Lawrence E., et al.. (2008). Review: Update on Selection of Optimal Radiopharmaceuticals for Clinical Trials. Cancer Biotherapy and Radiopharmaceuticals. 23(6). 797–806. 3 indexed citations

15.

Agazaryan, Nzhde, et al.. (2008). A Multi-center Consortium Study of Competing Platforms for Intracranial Stereotactic Irradiation. International Journal of Radiation Oncology*Biology*Physics. 72(1). S213–S213. 4 indexed citations

16.

Wong, Jeffrey Y.C., David Z. J. Chu, Lawrence E. Williams, et al.. (2006). A Phase I Trial of ⁹⁰ Y-DOTA-Anti-CEA Chimeric T84.66 (cT84.66) Radioimmunotherapy in Patients with Metastatic CEA-Producing Malignancies. Cancer Biotherapy and Radiopharmaceuticals. 21(2). 88–100. 38 indexed citations

17.

Olafsen, Tove, Vania Kenanova, Gobalakrishnan Sundaresan, et al.. (2005). Optimizing Radiolabeled Engineered Anti-p185HER2 Antibody Fragments for In vivo Imaging. Cancer Research. 65(13). 5907–5916. 123 indexed citations

18.

Crow, Desiree, Lawrence E. Williams, David Colcher, et al.. (2005). Combined Radioimmunotherapy and Chemotherapy of Breast Tumors with Y-90-Labeled Anti-Her2 and Anti-CEA Antibodies with Taxol. Bioconjugate Chemistry. 16(5). 1117–1125. 26 indexed citations

19.

Williams, Lawrence E., Anna M. Wu, Paul J. Yazaki, et al.. (2001). Numerical Selection of Optimal Tumor Imaging Agents with Application to Engineered Antibodies. Cancer Biotherapy and Radiopharmaceuticals. 16(1). 25–35. 48 indexed citations

20.

Williams, Lawrence E., et al.. (1995). A Shielded, Automated Injector for Energetic Beta-Emitting Radionuclides. Journal of Nuclear Medicine Technology. 23(1). 29–32. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact